Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for... see more

Recent & Breaking News (NDAQ:XAIR)

Beyond Air® Announces Two Appointments to Beyond Cancer(TM) Board of Directors

GlobeNewswire February 3, 2022

Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast

GlobeNewswire January 27, 2022

Beyond Air® Provides Regulatory Update for LungFit® PH

GlobeNewswire December 9, 2021

Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

GlobeNewswire December 1, 2021

Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer(TM) Private Placement

GlobeNewswire November 18, 2021

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022

GlobeNewswire November 11, 2021

Beyond Air® Announces Formation of Beyond Cancer(TM), a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors

GlobeNewswire November 4, 2021

Beyond Air® to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 2, 2021

Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast

GlobeNewswire October 25, 2021

Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease

GlobeNewswire October 20, 2021

Beyond Air® Provides Global Regulatory Update for LungFit® PH

GlobeNewswire September 21, 2021

Beyond Air® to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GlobeNewswire September 14, 2021

Beyond Air® Announces CFO Transition

GlobeNewswire August 20, 2021

OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

PR Newswire March 13, 2019

AIT Therapeutics to Participate at Two Investor Conferences in March

GlobeNewswire March 13, 2019

AIT Therapeutics Reports Financial Results for Fiscal Third Quarter 2019

GlobeNewswire February 13, 2019

AIT Therapeutics Announces Appointment of Robert F. Carey to Board of Directors

GlobeNewswire February 11, 2019

AIT Therapeutics Schedules Fiscal Third Quarter 2019 Financial Results Conference Call and Webcast

GlobeNewswire February 5, 2019

AIT Receives $3.15 Million Milestone Payment from Commercialization Partner Circassia Pharmaceuticals

GlobeNewswire February 4, 2019

AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China

GlobeNewswire January 24, 2019